Cancer immunogenomics is an emerging field that bridges genomics and immunology. The
establishment of large-scale genomic collaborative efforts along with the development of …

The field of cancer neoantigen investigation has developed swiftly in the past decade.
Predicting novel and true neoantigens derived from large multi-omics data became difficult …

Alternative splicing (AS) is prevalent in cancer, generating an extensive but largely
unexplored repertoire of novel immunotherapy targets. We describe I soform peptides from …

Immunotherapy has emerged as a crucial strategy to combat cancer by “reprogramming” a
patient's own immune system. Although immunotherapy is typically reserved for patients with …

Background Neoantigens are critical for anti-tumor immunity and have been long-
envisioned as promising therapeutic targets. However, current neoantigen analyses mostly …

Motivation Elimination of cancer cells by T cells is a critical mechanism of anti-tumor
immunity and cancer immunotherapy response. T cells recognize cancer cells by …

In diseases such as cancer, the design of new therapeutic strategies requires extensive,
costly, and unfortunately sometimes deadly testing to reveal life threatening off-target effects …

Tumor-specific antigens, also known as neoantigens, have potential utility in anti-cancer
immunotherapy, including immune checkpoint blockade (ICB), neoantigen-specific T cell …

Neoantigens have emerged as promising targets for cutting-edge immunotherapies, such as
cancer vaccines and adoptive cell therapy. These neoantigens are unique to tumors and …

Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of
hematologic malignancies, achieving remarkable clinical success with FDA-approved …